The Life Sciences team advised MBX Biosciences in its upsized initial public offering at a price to the public of $16.00 per share. 11,730,000 of its common stock at the public price per share, includes 1,530,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The aggregate gross proceeds to MBX Biosciences from the offering were approximately $187.7 million, before deducting underwriting discounts and commissions and offering expenses.
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. MBX Biosciences was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, MBX Biosciences designed its proprietary Precision Endocrine PeptideTM, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. MBX Biosciences in based in Carmel, Indiana.
The Goodwin team was led by Mitch Bloom, Edwin O’Connor, Dan Hughes, Kristen McCarthy, Eunice Chang and Austin Church; Duncan Greenhalgh, Ginggi Storer, Alexandra Haas and Lily Xu; Julie Tibbets and AJ Stautz; Heath Roosevelt Ingram; Sarah Bock, Eric Graffeo, Benjamin Kurrass and Justine Park; Christina Lewis and Alastair Papworth; Janet Andolina, Chris Zhao and Tyler Mayo; Jacqueline Klosek and Jacob Lee; Tim Worden, Lucy Sharples and Luke Nauth; Caroline Bullerjahn, Jennifer Luz and Marco Wong; Cecelia Lockner and Brian H. Mukherjee; Ettore A. Santucci; with invaluable assistance from James Matarese, Kathryn Clerici, Ryan Donahoe, Li Chang, Cody Foster and Jo-an Chen.
For additional information on the closing, please read the press release.